Table 3.
Grade 3 and higher hematologic and non-hematologic adverse events reported as at least possibly related to protocol therapy in the first cycle in Phase 2 and Oral Solution cohorts.
| Adverse Event | Phase 2 (n = 20) | Oral Solution (n = 12) | ||
|---|---|---|---|---|
| Grade 3 | Grade 4 | Grade 3 | Grade 4 | |
| Hematologic | ||||
| Neutropenia | 50% | 20% | 17% | 42% |
| Thrombocytopenia | 15% | 40% | 33% | |
| Lymphopenia | 25% | 10% | 8% | 17% |
| Leukopenia | 25% | 15% | 17% | 25% |
| Anemia | 15% | 33% | ||
| Non-hematologic | ||||
| Diarrhea | 20% | 8% | ||
| AST elevation | 5% | 8% | ||
| ALT elevation | 5% | |||
| Nausea | 8% | |||
| Hypoalbuminemia | 8% | |||
| Pleural effusion | 8% | |||
| Febrile neutropenia | 8% | |||
| Vomiting | 5% | |||
| Dehydration | 5% | |||